The Unsung Vytorin Victim: Primary-Care Marketing

FDA's defense of LDL-lowering as a surrogate marker is helping Schering/Merck stop the bleeding in its Vytorin franchise. But it doesn't change a more disturbing fact for Big Pharma marketers: the reaction to ENHANCE is only the latest warning sign that the simple marketing messages on which blockbusters are built may be a thing of the past. (This article first appeared in In Vivo, February 2008.)

Roger Longman

Not quite three weeks after triggering a medico-commercial earthquake with the ENHANCE trial results, Schering-Plough Corp. and Merck...

More from Clinical Trials

More from R&D

  • India Tightens Oversight Of CROs With Mandatory Registration

     
    • By 

    Contract research organizations (CROs) in India must gear up to comply with new registration requirements coming into effect in April 2025 that aim to enhance the quality and integrity of clinical trials, as well as of any bioavailability and bioequivalence studies conducted by them.

  • Clinical Trial Diversity Action Plans Need Timely FDA Feedback, Groups Say

     
    • By 

    The agency also should explain the potential consequences for sponsors if enrollment goals are not met, stakeholders say in comments on the DAP draft guidance. Some commenters urged the FDA to apply waiver criteria flexibly, especially for rare diseases.

  • How To Decarbonize Pharma R&D

     

    As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.